Annals of oncology : official journal of the European Society for Medical Oncology

The most recent articles from: Ann. Oncol. September 2019

Ann. Oncol. · Sep 2019

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.

The CDK4/6 inhibitor palbociclib prolongs progression-free survival in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer when combined with endocrine therapy. This phase II trial was designed to determine the feasibility of adjuvant palbociclib and endocrine therapy for early breast cancer. ⋯ NCT02040857.

explore further… or just mark as read…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.